Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615680934> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2615680934 endingPage "264" @default.
- W2615680934 startingPage "264" @default.
- W2615680934 abstract "The heterogeneity of hepatitis C virus (HCV) is due to the continuous and high replication rate, the low fidelity of the RNA-dependent RNA polymerase, and the immune surveillance of the host. Interleukin-12 (IL-12) plays a central role in mounting an effective cellular immune response directed towards elimination of intracellular pathogens. The effect of IL-12 on hepatitis C viremia and the HCV quasispecies population is unknown. In this study, 12 patients (9 males, 3 females; mean age: 44 ± 11 years), all virological non-responders to previous IFN-α treatment, received recombinant human IL-12 s.c. once weekly for 10 weeks stratified to three dose schedules (0.03 μg/kg, 0.1 μg/kg, and 0.5 μg/kg body weight, respectively). Fourteen IFN-α non-responders and 14 untreated patients served as age- and sex-matched controls. Serum HCV RNA concentrations and HCV quasispecies distribution were measured serially by quantitative reverse transcription - polymerase chain reaction and single strand conformation polymorphism analysis of the hypervariable region of the second envelope gene, respectively. Serum ALT and median HCV RNA levels before treatment (52.7 ± 21.7 U/L; 2.6 × 106 copies/mL) showed no significant changes during IL-12 treatment (57.3 ± 58.8 U/L and 3.2 × 106 copies/mL, 50.3 ± 46.2 U/L and 3.1 × 106 copies/mL, and 46.8 ± 35.3 U/L and 3.9 × 106 copies/mL at weeks 1, 4, and 10, respectively). Similar results were observed in 14 IFN-α non-responders and 14 untreated patients. However, changes in HCV quasispecies occurred in 10/12 (83%) and 9/14 (64%) patients treated with interleukin-12 and interferon-α, respectively, but only in 3/14 (21%) untreated subjects (P < 0.003 and P < 0.03). These results imply that interleukin-12 exerts only limited antiviral activity against certain HCV quasispecies in vivo. J. Med. Virol. 60:264–268, 2000. © 2000 Wiley-Liss, Inc." @default.
- W2615680934 created "2017-05-26" @default.
- W2615680934 creator A5010474616 @default.
- W2615680934 creator A5038545289 @default.
- W2615680934 creator A5045146362 @default.
- W2615680934 creator A5045504446 @default.
- W2615680934 creator A5059027618 @default.
- W2615680934 date "2000-03-01" @default.
- W2615680934 modified "2023-09-26" @default.
- W2615680934 title "Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virusPresented in part: 49th American Association for the Study of Liver Diseases meeting, Chicago, IL, 6–10 November 1998 (abstract # 1239)" @default.
- W2615680934 doi "https://doi.org/10.1002/(sici)1096-9071(200003)60:3<264::aid-jmv3>3.3.co;2-a" @default.
- W2615680934 hasPublicationYear "2000" @default.
- W2615680934 type Work @default.
- W2615680934 sameAs 2615680934 @default.
- W2615680934 citedByCount "0" @default.
- W2615680934 crossrefType "journal-article" @default.
- W2615680934 hasAuthorship W2615680934A5010474616 @default.
- W2615680934 hasAuthorship W2615680934A5038545289 @default.
- W2615680934 hasAuthorship W2615680934A5045146362 @default.
- W2615680934 hasAuthorship W2615680934A5045504446 @default.
- W2615680934 hasAuthorship W2615680934A5059027618 @default.
- W2615680934 hasConcept C104317684 @default.
- W2615680934 hasConcept C135763542 @default.
- W2615680934 hasConcept C14500911 @default.
- W2615680934 hasConcept C159047783 @default.
- W2615680934 hasConcept C203014093 @default.
- W2615680934 hasConcept C2522874641 @default.
- W2615680934 hasConcept C2776185481 @default.
- W2615680934 hasConcept C2776408679 @default.
- W2615680934 hasConcept C2776455275 @default.
- W2615680934 hasConcept C2781463415 @default.
- W2615680934 hasConcept C2908647359 @default.
- W2615680934 hasConcept C40767141 @default.
- W2615680934 hasConcept C55493867 @default.
- W2615680934 hasConcept C71924100 @default.
- W2615680934 hasConcept C86803240 @default.
- W2615680934 hasConcept C8891405 @default.
- W2615680934 hasConcept C99454951 @default.
- W2615680934 hasConceptScore W2615680934C104317684 @default.
- W2615680934 hasConceptScore W2615680934C135763542 @default.
- W2615680934 hasConceptScore W2615680934C14500911 @default.
- W2615680934 hasConceptScore W2615680934C159047783 @default.
- W2615680934 hasConceptScore W2615680934C203014093 @default.
- W2615680934 hasConceptScore W2615680934C2522874641 @default.
- W2615680934 hasConceptScore W2615680934C2776185481 @default.
- W2615680934 hasConceptScore W2615680934C2776408679 @default.
- W2615680934 hasConceptScore W2615680934C2776455275 @default.
- W2615680934 hasConceptScore W2615680934C2781463415 @default.
- W2615680934 hasConceptScore W2615680934C2908647359 @default.
- W2615680934 hasConceptScore W2615680934C40767141 @default.
- W2615680934 hasConceptScore W2615680934C55493867 @default.
- W2615680934 hasConceptScore W2615680934C71924100 @default.
- W2615680934 hasConceptScore W2615680934C86803240 @default.
- W2615680934 hasConceptScore W2615680934C8891405 @default.
- W2615680934 hasConceptScore W2615680934C99454951 @default.
- W2615680934 hasIssue "3" @default.
- W2615680934 hasLocation W26156809341 @default.
- W2615680934 hasOpenAccess W2615680934 @default.
- W2615680934 hasPrimaryLocation W26156809341 @default.
- W2615680934 hasRelatedWork W2009787120 @default.
- W2615680934 hasRelatedWork W2022485770 @default.
- W2615680934 hasRelatedWork W2029008013 @default.
- W2615680934 hasRelatedWork W2038697911 @default.
- W2615680934 hasRelatedWork W2065533615 @default.
- W2615680934 hasRelatedWork W2097883855 @default.
- W2615680934 hasRelatedWork W2106232291 @default.
- W2615680934 hasRelatedWork W2406675869 @default.
- W2615680934 hasRelatedWork W2899458078 @default.
- W2615680934 hasRelatedWork W794648307 @default.
- W2615680934 hasVolume "60" @default.
- W2615680934 isParatext "false" @default.
- W2615680934 isRetracted "false" @default.
- W2615680934 magId "2615680934" @default.
- W2615680934 workType "article" @default.